TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05496296

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Altrazeal® Transforming Powder Dressing
Description: Pressure injury wounds will be evaluated at each study visit (cleaned, photographed, measured) and a dressing will be applied according to the study arm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Altrazeal® Transforming Powder Dressing
Description: Pressure injury wounds will be evaluated at each study visit (cleaned, photographed, measured) and a dressing will be applied according to the study arm
Study: NCT05374499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Dosage: 3 mL Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% bupivacaine with 1:100,000 epinephrine
Description: Dosage: 3 mL of diluted 0.5% bupivacaine with 1:200,000 epinephrine (2:1 ratio of saline to standard bupivacaine) Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
Study: NCT04945616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin、clopidogrel、placebo or SHR2285
Description: groupA： Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin、clopidogrel、placebo or SHR2285
Description: groupB： Aspirin + clopidogrel + placebo or SHR2285 (dose 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin、ticagrelor、placebo or SHR2285
Description: groupC： Aspirin + ticagrelor + placebo or SHR2285
Study: NCT06492811

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GAT@F nanoenzyme hydrogel complex
Description: The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAT@F nanoenzyme hydrogel complex
Description: The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GAT@F nanoenzyme hydrogel complex
Description: The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.
Study: NCT05913921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B liposome for injection
Description: IV infusion, 2.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B liposome for injection
Description: IV infusion, 2.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AmBisome
Description: IV infusion, 2.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AmBisome
Description: IV infusion, 2.0 mg/kg
Study: NCT05466019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)
Description: FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ, Q2W Toripalimab 3mg/kg, intravenously administered on the first day of each cycle, Q2W.
Study: NCT05317949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated neuromuscular training program group
Description: Integrated neuromuscular training program group will do plyometric training, speed and sensitivity training, resistance training for 3 days in a week and total for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General fitness exercises program group
Description: General fitness exercises program group will do general fitness exercise for 3 days in a week and total for eight weeks.
Study: NCT05527249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: 20g of protein powder + 650mg of pomegranate extracts
Study: NCT03834909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose Truvada®
Description: TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, one tablet each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnancy-adjusted dose Truvada®
Description: TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, two tablets each day
Study: NCT05527249

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of the dietary supplement
Description: 20g of protein powder + 650mg of maltodextrin
Study: NCT05148949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard dosage inactivated vaccine
Description: This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard dosage inactivated vaccine
Description: This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosage inactivated vaccine
Description: This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double dosage inactivated vaccine
Description: This vaccine contains 1200 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double dosage inactivated vaccine
Description: This vaccine contains 1200 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
Study: NCT04865419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0466
Description: AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0466
Description: AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole film-coated tablet will be administered orally.
Study: NCT05721521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spin Bike Exercise
Description: 30 minute spin bike class led by a qualified instructor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spin Bike Exercise
Description: 30 minute spin bike class led by a qualified instructor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spin Bike Exercise
Description: 30 minute spin bike class led by a qualified instructor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 30 minute completing seated activities (e.g., wordsearches)
Study: NCT04747899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positional release technique
Description: Experimental group is given Positional Release Technique along with the hot pack, muscle stretching and posture correction.~Positional release technique position will maintained for almost 90 seconds. This technique will be repeated for three times each session, with 10 sec relaxation, 3 days/week.~Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions were given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles.
Study: NCT05244902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Dextrose
Description: All the patients will receive oral 3mL/kg 5%Dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Dextrose
Description: All the patients will receive oral 3mL/kg 5%Dextrose
Study: NCT04536779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in the local departments of TT and cycling trips with CUA
Description: in a minimum of 3 months, the individuals with low physical mobility will conduct a minimum of 8-10 training and cycling sessions.
Study: NCT05872165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phonophoresis
Description: 1 MHz, 1 W/cm2continuous mode of ultrasound therapy for 5 min. using ozonated gel as a coupling medium

Intervention type: OTHER
Group type: OTHER
Intervention: conventional physical therapy
Description: conventional TENS (100 Hz) for 30 min - hot pack for 20 min- stretching and strengthening exercises, wrist rest splints 3times per week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: conventional TENS (100 Hz) for 30 min - hot pack for 20 min- stretching and strengthening exercises, wrist rest splints 3times per week for 4 weeks.
Study: NCT04855682

Intervention type: OTHER
Intervention: Retrospective observation after 24 months after the spinal procedure
Description: Retrospective evaluation of patients before the procedure, and prospective evaluation of patients 24 months after the spinal procedure, comparing the MRI changes and procedure impact on fatty muscle degeneration process

Intervention type: OTHER
Intervention: Retrospective observation after 24 months after the spinal procedure
Description: Retrospective evaluation of patients before the procedure, and prospective evaluation of patients 24 months after the spinal procedure, comparing the MRI changes and procedure impact on fatty muscle degeneration process

Intervention type: OTHER
Intervention: Retrospective observation after 24 months after the spinal procedure
Description: Retrospective evaluation of patients before the procedure, and prospective evaluation of patients 24 months after the spinal procedure, comparing the MRI changes and procedure impact on fatty muscle degeneration process

Intervention type: OTHER
Intervention: Retrospective observation after 12 months after the spinal procedure
Description: Retrospective evaluation of the patient status before the procedure, and prospective evaluation of patients for 12 months after the spinal procedure, comparing the MRI changes

Intervention type: OTHER
Intervention: Retrospective observation after 12 months after the spinal procedure
Description: Retrospective evaluation of the patient status before the procedure, and prospective evaluation of patients for 12 months after the spinal procedure, comparing the MRI changes

Intervention type: OTHER
Intervention: Retrospective observation after 12 months after the spinal procedure
Description: Retrospective evaluation of the patient status before the procedure, and prospective evaluation of patients for 12 months after the spinal procedure, comparing the MRI changes

Intervention type: OTHER
Intervention: Prospective evaluation of patients after 12 and 24 months after the spinal procedure
Description: Prospective evaluation of patients after 12 and 24 months after the spinal procedure, comparing the MRI changes

Intervention type: OTHER
Intervention: Prospective evaluation of patients after 12 and 24 months after the spinal procedure
Description: Prospective evaluation of patients after 12 and 24 months after the spinal procedure, comparing the MRI changes

Intervention type: OTHER
Intervention: Prospective evaluation of patients after 12 and 24 months after the spinal procedure
Description: Prospective evaluation of patients after 12 and 24 months after the spinal procedure, comparing the MRI changes
Study: NCT04884204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lee Symptom Scala
Description: Symptom identification and management with Lee Symptom Scale in follow up care
Study: NCT05375045

Intervention type: DEVICE
Intervention: dental implantation
Description: an implant is surgically inserted into the maxilla or mandible, and then an abutment is connected to this implant to support the dental prosthesis.
Study: NCT05151874

Intervention type: DRUG
Intervention: Abobotulinum toxin A
Description: To measure ROM evolution in patients with post-stroke spasticity in the upper limb with spasticity pattern III.
Study: NCT05054985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Branched Thoracoabdominal Stent Graft System
Description: Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with multi-branched thoracoabdominal stent graft system .
Study: NCT04747899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: Hot pack for 15-mins. Upper trapezius stretching 5 repetitions×1 set, 3 days/ week. Total of 3 sessions are given each consisting of 30 min.~Posture correction in ADLs as well as in working place by advising correct sitting posture, the participants will advised to relieve muscle tension after every 20-30 minutes of work by getting up; stretching the arm, shoulder, neck, and back muscles.
Study: NCT06025006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alternative to incarceration
Description: place of respite with housing plus intensive follow-up
Study: NCT05929287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tablet-based CT
Description: This group will perform digital CT tasks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paper-and-pencil CT group
Description: This group will perform paper-and-pencil CT tasks.
Study: NCT06361589

Intervention type: DRUG
Intervention: Lorlatinib
Description: lolatinib 100mg qd po
Study: NCT04930900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARS-1 with URTI
Description: ARS-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARS-1 without URTI
Description: ARS-1 without URTI
Study: NCT06024603

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Drug Sensitivity Test (DST)
Description: Refractory cancer tissue will be collected from participants and subjected to single-drug testing while DNA is simultaneously sent for targeted gene sequencing. Drug sensitivity scores from the tests will become available for a final list of therapeutic options ranked best in order of preference together with suggested doses and schedules.
Study: NCT05179239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
Description: SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
Description: SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + paclitaxel + cisplatin/carboplatin ± BP102
Description: Placebo + paclitaxel + cisplatin/carboplatin ± BP102
Study: NCT06242301

Intervention type: OTHER
Group type: OTHER
Intervention: The collective person-centered dialogue intervention
Description: * Educate and train the interdisciplinary team and staff.~* Upon hospitalisation, the interdisciplinary team introduces an interactive dialogue tool to patients and their relatives. The tool is designed to facilitate a person-centered dialogue and assess the patients' needs, motivations, and challenges regarding eating and physical activity during hospitalization and in everyday settings.~* Following the needs assessment, the interdisciplinary team will introduce and initiate a personalised action plan based on a predefined template that includes suggestions for actions related to the needs assessment.~* Collaboratively, the interdisciplinary team, patients, and relatives evaluate and adjust the action plan, discussing relevant actions and potential community support for maintaining daily activities.~* Before discharge, discussions are guided by predefined questions. Patients receive a contact number for follow-up and information on oral nutritional supplementation prescriptions.
Study: NCT05067387

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Oral THC (20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Oral CBD (20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC + CBD
Description: Oral THC (20 mg) + CBD (20 mg)
Study: NCT05839808

Intervention type: OTHER
Group type: OTHER
Intervention: Reliability and validity study
Description: To evaluate the validity and reliability of the Stroke Exercise Preference Inventory
Study: NCT04721210

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: The investigated method is called transcranial magnetic The impact on the SMA will be made using a special inductor of the double conical coil type. Navigation will be carried out through the use of the international system 10-20%. The threshold of motor response will be determined by stimulating the motor area of the legs with the intensity of stimulation necessary to trigger a motor response with an amplitude of more than 50 mv.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: The investigated method is called transcranial magnetic The impact on the SMA will be made using a special inductor of the double conical coil type. Navigation will be carried out through the use of the international system 10-20%. The threshold of motor response will be determined by stimulating the motor area of the legs with the intensity of stimulation necessary to trigger a motor response with an amplitude of more than 50 mv.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: The investigated method is called transcranial magnetic The impact on the SMA will be made using a special inductor of the double conical coil type. Navigation will be carried out through the use of the international system 10-20%. The threshold of motor response will be determined by stimulating the motor area of the legs with the intensity of stimulation necessary to trigger a motor response with an amplitude of more than 50 mv.
Study: NCT05919888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Applied to skin incision.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SURGX Wound Gel
Description: Applied to skin incision.
Study: NCT04903535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alonefire SV003 10W 365nm UV Flashlight
Description: Investigator will use a Nitric Oxide Analyzer while attached to a small suction port on the subject's ear lobe to be tested for Nitric Oxide. After getting the baseline assay, the investigator will shine a low-intensity UV Flashlight (Alonefire SV003 10W 365nm UV Flashlight) at the ear lobe for 10 seconds, repeated three times at 20 second intervals, to determine if there is photobleaching. Then the assay will then be performed on the opposite ear lobe. Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). Fifteen minutes after the third UV flashlight exposure, the investigator will collect air from the subject's ear during photolysis into a 20mL glass syringe (once from each ear). The subject and the investigator will wear UV goggles during the experiment.
Study: NCT05662982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Northwestern University Flexible Subischial Suction Socket (NU-FlexSIS)
Description: A custom-made prosthetic socket for transfemoral amputation that consists of proximal trimlines that do not interact with the pelvis.
Study: NCT04502563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring and predictive analytics
Description: Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
Study: NCT06049199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech Enhancer
Description: Speech Enhancer is an adaptive feature which increases the amplitude of speech signal when speech is detected. Speech Enhancer will be switched on and off for the Intervention
Study: NCT03873922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet intervention
Description: Ketogenic, really low carbohydrate containing (15-20 g/day), meals will be offered to the participants.
Study: NCT06439160

Intervention type: OTHER
Intervention: Participants will be asked to complete a series of questionnaires at t0, t1 and t2
Description: Individuals will be people who voluntarily will take part in a residential three to six weeks multidisciplinary inpatient intensive rehabilitation treatment targeting the improvement of psychological well-being, body image, and psychopathology for anorexia nervosa.~Therefore, at T0 (at the beginning of the treatment) and T1 (at the end of the rehabilitation programme), participants will fill out some self-report questionnaires to evaluate the effect of the multidisciplinary inpatient intensive rehabilitation treatment on different outcomes (i.e. psychological well-being, eating pathology, body image, and comorbidities), among which their social components/skills. Moreover, we will ask participants to complete 3 months after discharge the questionnaires related to the social components/skills only. Participants will be contacted by email, within the email participants will find a link to click on for the completion of the questionnaires.
Study: NCT05374655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative blood glucose control
Description: Patients included in this group, under the guidance of endocrinologists, develop hypoglycemic strategies for patients, follow up and guide patients to take medication, review HbA1c levels after 6 weeks, perform surgical treatment if they meet preoperative HbA1c\<7.5%, continue hypoglycemic therapy if still above standards, and administer drugs according to the corresponding type of heart disease during this period.
Study: NCT06358768

Intervention type: OTHER
Intervention: teamwork job improvement overall
Description: increase of teamwork capacities and skills improvement